For research use only. Not for therapeutic Use.
Cadisegliatin (TTP-399) is a potential, orally active liver-selective glucokinase (GK) activator. Cadisegliatin has antihyperglycaemic activity. Cadisegliatin can be used for the research of type 2 diabetes[1][2].
Cadisegliatin (TTP-399) increases glucose metabolism in rat hepatocytes, the EC50 values of lactate and glycogen in 15 nM glucose are 2.39 μM and 2.64 μM, respectively[2].
TTP399 (200 mg/kg, per os, p.o.) has no effect on plasma glucose and insulin in fasted rats[2].
TTP399 (75 or 150 mg/kg, per day, for 4 weeks) improves glucose homeostasis in ob/ob mouse model[2].
TTP399 (50 mg/kg, per day, for 13 weeks) is effective in reducing plasma glucose during an oral glucose tolerance test (OGTT) in minipigs model[2].
| Catalog Number | I043416 |
| CAS Number | 859525-02-3 |
| Synonyms | 2-[[2-[[cyclohexyl-(4-propoxycyclohexyl)carbamoyl]amino]-1,3-thiazol-5-yl]sulfanyl]acetic acid |
| Molecular Formula | C21H33N3O4S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H33N3O4S2/c1-2-12-28-17-10-8-16(9-11-17)24(15-6-4-3-5-7-15)21(27)23-20-22-13-19(30-20)29-14-18(25)26/h13,15-17H,2-12,14H2,1H3,(H,25,26)(H,22,23,27) |
| InChIKey | HPGJSAAUJGAMLV-UHFFFAOYSA-N |
| SMILES | CCCOC1CCC(CC1)N(C2CCCCC2)C(=O)NC3=NC=C(S3)SCC(=O)O |
| Reference | [1]. International Nonproprietary Names for Pharmaceutical Substances (INN) [2]. Adrian Vella, et al. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. Sci Transl Med. 2019 Jan 16;11(475):eaau3441. |
